Dementia with Lewy bodies

References

Key articles

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Full text  Abstract

Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01190.Full text  Abstract

Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.Full text  Abstract

Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies: response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23(5):307-11. Abstract

O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68.Full text  Abstract

Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Full text  Abstract

McKeith I, Del-Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet. 2000 Dec 16;356(9247):2031-6. Abstract

Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71.Full text  Abstract

Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. Abstract

Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia: common features and differences [in German]. Med Monatsschr Pharm. 2011 Feb;34(2):47-52. Abstract

Reference articles

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Full text  Abstract

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition. (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 Nov;47(5):1113-24. Abstract

4. Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013 Dec 3;81(23):2032-8. Abstract

5. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005 Nov;34(6):561-6.Full text  Abstract

6. Rampello L, Cerasa S, Alvano A, et al. Dementia with Lewy bodies: a review. Arch Gerontol Geriatr. 2004 Jul-Aug;39(1):1-14. Abstract

7. Bogaerts V, Engelborghs S, Kumar-Singh S, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007 Sep;130(Pt 9):2277-91.Full text  Abstract

8. Ohara K, Takauchi S, Kokai M, et al. Familial dementia with Lewy bodies (DLB). Clin Neuropathol. 1999 Sep-Oct;18(5):232-9. Abstract

9. Rosenberg CK, Cummings TJ, Saunders AM, et al. Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathol. 2001 Dec;102(6):621-6. Abstract

10. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46Full text  Abstract

11. Samuel W, Galasko D, Masliah E, et al. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Jan;55(1):44-52. Abstract

12. Weisman D, Cho M, Taylor C, et al. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007 Jul 24;69(4):356-9. Abstract

13. Yamada T, Kadekaru H, Matsumoto S, et al. Prevalence of dementia in the older Japanese-Brazilian population. Psychiatry Clin Neurosci. 2002 Feb;56(1):71-5. Abstract

14. erman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004 Jan 27;62(2):181-7. Abstract

15. Fahn S, Elton RL; UPDRS program members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson’s disease. Vol 2. Florham Park, NJ: Macmillan Healthcare; 1987:153-163.

16. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. Abstract

17. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003 Jul 8;61(1):40-5. Abstract

18. Boeve BF, Silber MH, Parisi JE, et al. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):146-57.Full text  Abstract

19. Vendette M, Gagnon JF, Soucy JP, et al. Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov Disord. 2011 Aug 1;26(9):1717-24. Abstract

20. Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012 Oct;27(10):989-98. Abstract

21. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5). pii: PCC.11r01190.Full text  Abstract

22. Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.Full text  Abstract

23. Puñal Riobóo J, Varela Lema L, Serena Puig A, et al. Effectiveness of 123I-ioflupane (DaTSCAN) in the diagnosis of Parkinsonian syndromes: a systematic review [in Spanish]. Rev Esp Med Nucl. 2007 Nov-Dec;26(6):375-84. Abstract

24. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. Abstract

25. Bonanni L, Franciotti R, Nobili F, et al. EEG markers of dementia with Lewy bodies: a multicenter cohort study. J Alzheimers Dis. 2016 Oct 18;54(4):1649-57. Abstract

26. Janvin C, Larsen J, Salmon D, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord. 2006 Mar;21(3):337-42. Abstract

27. Tiraboschi P, Salmon D, Hansen L, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? 2006 Mar;129(Pt 3):729-35.Full text  Abstract

28. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol. 2006 Dec;19(6):572-9. Abstract

29. Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011 Aug 30;77(9):875-82. Abstract

30. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn. 1996 Jul;31(2):148-65. Abstract

31. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Full text

32. Watson R, Blamire AM, O'Brien JT. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord. 2009;28(6):493-506.Full text  Abstract

33. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007 Feb;27(1):42-7. Abstract

34. Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies: response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23(5):307-11. Abstract

35. Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015 Aug 1;172(8):731-42.Full text  Abstract

36. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.Full text  Abstract

37. Dickson DW. Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol. 2001 Aug;14(4):423-32. Abstract

38. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry. 2002 Feb;180:144-7.Full text  Abstract

39. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68.Full text  Abstract

40. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Full text  Abstract

41. McKeith I, Del-Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet. 2000 Dec 16;356(9247):2031-6. Abstract

42. Crecelius C. Diagnosis and treatment of non-Alzheimer's dementias. J Am Med Dir Assoc. 2003 Jul-Aug;4(4 Suppl):H25-9. Abstract

43. Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders. Curr Med Res Opin. 2008 Jan;24(1):157-66. Abstract

44. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71.Full text  Abstract

45. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S15-8. Abstract

46. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007 Jan;14(1):e1-26.Full text  Abstract

47. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009 Jul;8(7):613-8. Abstract

48. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. Abstract

49. Johansson CB, Ballard C, Hansson O, et al. Efficacy of memantine in PDD and DLB: An extension study including washout and open-label treatment. Int J Geriatr Psychiatry. 2011 Feb;26(2):206-13. Abstract

50. Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013 Jul;8(4):433-444.Full text  Abstract

51. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007 Jun 5;146(11):775-86. Abstract

52. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007 Feb 27;176(5):627-32.Full text  Abstract

53. Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia: common features and differences [in German]. Med Monatsschr Pharm. 2011 Feb;34(2):47-52. Abstract

54. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42.Full text  Abstract

55. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. 2005 Aug;20 Suppl 12:S77-82. Abstract

56. Kurtz AL, Kaufer DI. Dementia in Parkinson's disease. Curr Treat Options Neurol. 2011 Jun;13(3):242-54. Abstract

57. Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2014.Full text

58. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003 Jul;4(4):281-4. Abstract

59. McGrane IR, Leung JG, St Louis EK, et al. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015 Jan;16(1):19-26.Full text  Abstract

60. Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1200-3.Full text  Abstract

61. Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013 Jan 1;27(4):469-77.Full text  Abstract

62. Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010 Sep;16(8):522-6. Abstract

63. Orgeta V, Qazi A, Spector AE, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014 Jan 22;(1):CD009125.Full text  Abstract

64. Williams MM, Xiong C, Morris JC, et al Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67:1935-1941. Abstract

65. Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013;56:1-9. Abstract

Use of this content is subject to our disclaimer